Table 4 :  Immunomonitoring  and clinical follow up of filarial patients during DEC therapy.


Case No. Age & Sex Clinical presentation 
(Duration)		 Duration of DEC therapy
(Months)

Filarial antibody positivity

Filarial antigen positivity

 Clinical
Progress
Before DEC therapy After
DEC therapy		 Before DEC therapy After
DEC therapy
1. 37M Oedema Right foor (45days) Recurrent fever (45 days) 6 + - + - Recovered
2. 40F Fever, ADL and Oedema Right lower limb(10 days) 6 + - + - Recovered
3. 46F Bilateral oedema lower limb with intermittent pain (45 days) 12 + - ND - Minimal oedema persists
4. 34M Oedema  right lower limb (15 days) 3 + - - - Recovered
5. 48M Bilateral vaginal hydrocele (5 yrs) 6 + - + - Minimal hydrocele persists
6. 43M Epididymoorchitis & Funicilitis & Funiculitis (left) (4 months) 3 + - + - Recovered
7. 33M Dimness of vision Right eye Macu;ar oedema & CSR (2 months) 1 + - - - Recovered
8. 23M CSR with dimness 0f vision (3 months) 3 + - - - Recovered
9. 41 TPE (4 months) 6 + - + - Recovered
10. 20M TPE (1 month) 3 - - + - Recovered


 * DEC was administered 6 mg/kg body wt./day  for 21 days each month for 3-12 months    ADL -  Adenolymphangitis , CSR- Central   Serous     retinopathy ;  TPE-Tropica  pulmonary eosinophilia; ND=not done.



Table 5 : Duration of DEC treatment in different clinical presentations of filariasis followed for one year.

Clinical group treatment given in 

No. of cases studied

         Duration of DEC  (percentage of cases parentheses)

  Acute clinical filariasis : 
  Funiculitis, epididymoorchitis (acute), minimal hydrocele (acute), ADL (accute attack), lymphoe-  dema (< 45 days duration with  and without pain)

22



3 months (36 %)
6 months (55 %)
12 months (9 %)

  Chronic clinical filariasis:
Hydrocele , lymphoedema and  elephantiasis cases, chronic          ADL, chronic epididymoorchitis,   elephantiasis of  breast 		62

3 months (16 %)
6 months (61 %)
12 months (23 %)

Occult filariasis :   
TPE &  monoarthritis               

 5


3  months(20 %)
6  months(80 %)

Back                                                                           Next